QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.128587v1 324/1/15    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Supino, R. Articles by Zunino, F. Search for Related Content PubMed PubMed Citation Articles by Supino, R. Articles by Zunino, F.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Antimetastatic Effect of a Small-Molecule Vacuolar H⁺-ATPase Inhibitor in in Vitro and in Vivo Preclinical Studies

Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy (R.S., G.Pe., G.Pr., M.T., E.F., L.D.B., P.C., F.Z.); Facoltà Medicina Veterinaria Università degli Studi di Milano, Milan, Italy (E.R.); Consiglio Nazionale delle Ricerche, Università di Pavia, Pavia, Italy (A.C.C., G.B.); and Nikem Research, Baranzate, Milan, Italy (P.M., C.F.)

On the basis of the evidence that vacuolar H⁺-ATPase is implicated in the development of the metastatic phenotype, we have explored the possibility to target the enzyme function in an attempt to control the metastatic behavior of tumor cells. In this study, we used an indole derivative, NiK-12192 [4-(5,6-dichloro-1H-indol-2-yl)-3-ethoxy-N-(2,2,6,6-tetramethyl-piperidin-4-yl)-benzamide], recently identified as an effective inhibitor of vacuolar H⁺-ATPase, as a potential antimetastatic agent in the treatment of NSCLC H460 xenograft, which is able to induce lung metastases in mice. Oral administration of NiK-12192 caused a significant inhibition of formation of spontaneous metastases. In contrast, the drug exhibited a negligible effect on the development of artificial metastases (i.e., after i.v. injection of tumor cells), thus supporting that the drug affects the early events of the metastatic process (e.g., migration and invasion). Cellular effects are consistent with this interpretation. In conclusion, the available results show for the first time that a vacuolar H⁺-ATPase inhibitor is effective in modulation of the metastatic behavior of a lung carcinoma, supporting its potential therapeutic interest as a novel treatment approach.

Address correspondence to: Dr. Franco Zunino, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. E-mail: franco.zunino{at}istitutotumori.mi.it